ETF Series Solutions Trust Range Cancer Therapeutics ETF
CNCR
CNCR was delisted on the 27th of May, 2025.
15 hedge funds and large institutions have $1.58M invested in ETF Series Solutions Trust Range Cancer Therapeutics ETF in 2023 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 0 closing their positions.
7% more funds holding
Funds holding: 14 → 15 (+1)
0.56% less ownership
Funds ownership: 18.52% → 17.97% (-0.56%)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
27% less capital invested
Capital invested by funds: $2.15M → $1.58M (-$579K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$168K |
| 2 |
Osaic Holdings
Scottsdale,
Arizona
|
+$1.83K |
| 3 |
NA
NewEdge Advisors
New Orleans,
Louisiana
|
+$1.1K |
| 4 |
CG
Colony Group
Boston,
Massachusetts
|
+$610 |
| 5 |
BBPWM
Blue Bell Private Wealth Management
Blue Bell,
Pennsylvania
|
+$12 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$326K |
| 2 |
LPL Financial
San Diego,
California
|
-$48.8K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$35.7K |
| 4 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
-$31.7K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$10.6K |
CNCR Hedge Fund Activity: Q3 2023 in Review
15 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) for Q3 2023, worth a combined $1.58M — down 27% from $2.15M a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new CNCR positions and 0 closed out — a net gain of 1 holder — while 4 added to existing stakes and 5 trimmed.
The largest buyer was Jane Street, opening a new position worth an estimated $168K. The largest seller was Royal Bank of Canada, cutting an estimated $326K.
- 15 institutional investors held ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) as of Q3 2023, up from 14 in Q2 2023.
- Funds reported $1.58M of ETF Series Solutions Trust Range Cancer Therapeutics ETF stock for Q3 2023, down 27% quarter-over-quarter.
- 1 fund opened new ETF Series Solutions Trust Range Cancer Therapeutics ETF positions in Q3 2023 and 0 closed out, a net change of +1 holder.
- The largest ETF Series Solutions Trust Range Cancer Therapeutics ETF buyer in Q3 2023 was Jane Street, an estimated $168K added.
- The largest ETF Series Solutions Trust Range Cancer Therapeutics ETF seller in Q3 2023 was Royal Bank of Canada, an estimated $326K sold.
Based on aggregated 13F filings for Q3 2023.